Clinical trials
Follow clinical development from trial design and recruitment through results.
- Trial phase
- Status
- Readouts
Company intelligence / Profile preview
InflammaGen Therapeutics
Carmel Valley, California, United Statesigenrx.com ↗
- Ownership
- Private
- Employees
- ~8
- Development stage
- Other
01
Overview
Phase 2 pilot study of Shok-Pak initiated for multi-organ failure; preclinical and ex-US human data showed improved survival and recovery[1][3][5].
- Therapeutic areas
- CardiovascularOtherInfectious Diseases
- Modalities
- Small molecule
- Industry
- Biotech
02
Partnerships
Confidential discussions with two significant pharmaceutical players
Beyond the preview
Go deeper on InflammaGen Therapeutics.
Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.
Licensing & deals
Explore licensing agreements, acquisitions, and the assets behind each deal.
- Partners
- Deal terms
- Milestones
Funding history
Trace financing activity and the investors behind a company’s development.
- Funding rounds
- Investors
- Capital raised
Competitive landscape
Compare peer pipelines by target, modality, and therapeutic area.
- Peer companies
- Targets
- Pipeline overlap
Technologies & patents
Explore technology platforms and the patent landscape around relevant assets.
- Platforms
- Patents
- Assignees
Research & analysis
Connect company news and source material to the questions you’re investigating.
- Company news
- Sources
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on InflammaGen Therapeutics.